Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Silvia Catellani, Ivana Pierri, Marco Gobbi, Alessandro Poggi, Maria Raffaella Zocchi
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/43a888f74f0d45ed92183b04cada8d05
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43a888f74f0d45ed92183b04cada8d05
record_format	dspace
spelling	oai:doaj.org-article:43a888f74f0d45ed92183b04cada8d052021-11-18T06:55:38ZImatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.1932-620310.1371/journal.pone.0018925https://doaj.org/article/43a888f74f0d45ed92183b04cada8d052011-04-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21533122/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic phase of disease, treated with imatinib mesylate, were analyzed. Bone marrow aspirates were drawn at diagnosis, after 3, 6, 12, 18 months for haematological, cytofluorimetric, cytogenetic, biomolecular evaluation and cytokine measurement. Responder and non responder patients were defined according to the European LeukemiaNet recommendations. In responder patients (n = 32), the percentage of bone marrow CD20(+)CD5(+)sIgM(+) lymphocytes, and the plasma levels of IgM, were significantly higher, at 3 months and up to 9 months, than in non responders. These IgM reacted with O-linked sugars expressed by leukemic cells and could induce tumor cell apoptosis. In responder patients the stromal-derived factor-1 and the B-lymphocyte-activating factor of the tumor necrosis factor family significantly raised in the bone marrow after imatinib administration, together with the bone morphogenetic proteins-2 and -7. All patients with high number of CD20(+)CD5(+)sIgM(+) cells and high stromal-derived factor-1 and B lymphocyte activating factor levels, underwent complete cytogenetic and/or molecular remission by 12 months. We propose that CD20(+)CD5(+)sIgM(+) lymphocytes producing anti-carbohydrate antibodies with anti-tumor activity, might contribute to the response to imatinib treatment. As in multivariate analysis bone marrow CD20(+)CD5(+)sIgM(+) cells and stromal-derived factor-1 and B-lymphocyte-activating factor levels were significantly related to cytogenetical and molecular changes, they might contribute to the definition of the pharmacological response.Silvia CatellaniIvana PierriMarco GobbiAlessandro PoggiMaria Raffaella ZocchiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 4, p e18925 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Silvia Catellani Ivana Pierri Marco Gobbi Alessandro Poggi Maria Raffaella Zocchi Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
description	Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic phase of disease, treated with imatinib mesylate, were analyzed. Bone marrow aspirates were drawn at diagnosis, after 3, 6, 12, 18 months for haematological, cytofluorimetric, cytogenetic, biomolecular evaluation and cytokine measurement. Responder and non responder patients were defined according to the European LeukemiaNet recommendations. In responder patients (n = 32), the percentage of bone marrow CD20(+)CD5(+)sIgM(+) lymphocytes, and the plasma levels of IgM, were significantly higher, at 3 months and up to 9 months, than in non responders. These IgM reacted with O-linked sugars expressed by leukemic cells and could induce tumor cell apoptosis. In responder patients the stromal-derived factor-1 and the B-lymphocyte-activating factor of the tumor necrosis factor family significantly raised in the bone marrow after imatinib administration, together with the bone morphogenetic proteins-2 and -7. All patients with high number of CD20(+)CD5(+)sIgM(+) cells and high stromal-derived factor-1 and B lymphocyte activating factor levels, underwent complete cytogenetic and/or molecular remission by 12 months. We propose that CD20(+)CD5(+)sIgM(+) lymphocytes producing anti-carbohydrate antibodies with anti-tumor activity, might contribute to the response to imatinib treatment. As in multivariate analysis bone marrow CD20(+)CD5(+)sIgM(+) cells and stromal-derived factor-1 and B-lymphocyte-activating factor levels were significantly related to cytogenetical and molecular changes, they might contribute to the definition of the pharmacological response.
format	article
author	Silvia Catellani Ivana Pierri Marco Gobbi Alessandro Poggi Maria Raffaella Zocchi
author_facet	Silvia Catellani Ivana Pierri Marco Gobbi Alessandro Poggi Maria Raffaella Zocchi
author_sort	Silvia Catellani
title	Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
title_short	Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
title_full	Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
title_fullStr	Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
title_full_unstemmed	Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
title_sort	imatinib treatment induces cd5+ b lymphocytes and igm natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/43a888f74f0d45ed92183b04cada8d05
work_keys_str_mv	AT silviacatellani imatinibtreatmentinducescd5blymphocytesandigmnaturalantibodieswithantileukemicreactivityinpatientswithchronicmyelogenousleukemia AT ivanapierri imatinibtreatmentinducescd5blymphocytesandigmnaturalantibodieswithantileukemicreactivityinpatientswithchronicmyelogenousleukemia AT marcogobbi imatinibtreatmentinducescd5blymphocytesandigmnaturalantibodieswithantileukemicreactivityinpatientswithchronicmyelogenousleukemia AT alessandropoggi imatinibtreatmentinducescd5blymphocytesandigmnaturalantibodieswithantileukemicreactivityinpatientswithchronicmyelogenousleukemia AT mariaraffaellazocchi imatinibtreatmentinducescd5blymphocytesandigmnaturalantibodieswithantileukemicreactivityinpatientswithchronicmyelogenousleukemia
_version_	1718424162909814784

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Ejemplares similares